Who this course is for:
This course will be valuable for trainees in paediatric oncology, trainees in general paediatrics and other specialties which are involved in the management of neuroblastoma for example clinical oncology and paediatric surgery, clinical nurse specialists and clinical trials staff. It will also be of value for consultants in shared care paediatrics and paediatric oncology, and a range of other specialties requiring CPD in this area.
Learning objectives:
At the end of the course, participants will have a good overview of the various subtypes of neuroblastoma, the importance of pathology and imaging in assigning a risk category to guide the treatment strategy and inform prognosis, the different contributions of all members of the multi-disciplinary team, and the range of treatments used in the first line management of neuroblastoma, and in the setting of refractory or relapsed disease. Additionally, attendees will understand the evidence base underlying current treatments, and the critical importance of international cooperation and clinical trials in improving the prospects for cure, and in diminishing the toxicity of treatment.
Course structure:
This is a two-day course. It comprises a series of interactive talks from experts in different aspects of neuroblastoma, with case discussions to ensure that the content is related to clinical patient management. The oral sections will be supplemented by written information, and pointers to further learning. The residential option will allow participants to interact informally with the faculty in the evening, to learn more.
To register click here